AI-Based Model May Guide Decision-Making in Kidney Cancer Based on CT, EGFRMarch 17th 2023
Data demonstrate the feasibility of automated glomerular filtration rate prediction to decide between partial nephrectomy and radical nephrectomy in kidney cancer, according to an expert from the Cleveland Clinic.
Efforts are Underway to Tackle Immunotherapy Resistance in Refractory RCCMarch 14th 2023
Increasing cancer antigen presentation as well as working with tumor cells in and delivering novel cells to the microenvironment may help in overcoming mechanisms of immune checkpoint inhibitor resistance in refractory renal cell carcinoma.
Ipilimumab Yields ‘Limited Effect’ in Refractory Kidney Cancer SubtypeMarch 12th 2023
Ipilimumab monotherapy does not appear effective in driving complete responses in refractory renal cell carcinoma despite yielding some progression-free survival intervals, according to an expert from the University of Texas Southwestern Medical Center.
Expert Highlights Armamentarium of Advanced Kidney Cancer TherapiesMarch 11th 2023
An expert from the University of Texas Southwestern Medical Center discusses several phase 3 clinical trials supporting the use of various single-agent and combination immunotherapy regimens for advanced kidney cancer.
BXCL701/Pembrolizumab Yields Durable Responses in Prostate Cancer SubtypeMarch 10th 2023
All patients with platinum-resistant, small-cell neuroendocrine prostate cancer who responded to treatment with BXCL701 plus pembrolizumab were microsatellite stable and/or tumor mutational burden–low with a low probability of response to pembrolizumab.
Genomic Analysis Yields ‘Hypothesis Generating’ Data in Bladder Cancer SubtypeFebruary 26th 2023
An expert from Chase Comprehensive Cancer Center discusses how findings from a genomic analysis of the phase 2 BLASST-1 trial may identify biomarkers of response and resistance to nivolumab/chemotherapy in muscle-invasive bladder cancer.
TFS Improves With Nivolumab, Salvage Nivolumab in Advanced Renal Cell CarcinomaFebruary 21st 2023
Results from cohort A of the HCRN GU16-260 trial showed treatment-free survival was enhanced in patients with advanced renal cell carcinoma who received nivolumab monotherapy plus salvage nivolumab and ipilimumab maintenance.
PET/CT Imaging Agent Demonstrates Real-World Specificity/Sensitivity in RCCFebruary 20th 2023
89Zr-DFO-girentuximab improves sensitivity and specificity in identifying clear cell kidney cancer compared with any metric to date, according to an expert from the University of California, Los Angeles.
Frontline Cabozantinib Yields Early Responses After CPI Combos in RCCFebruary 19th 2023
Patients with locally advanced or metastatic renal cell carcinoma with a clear-cell component who receive first-line cabozatinib after checkpoint inhibitor combination therapy appear to have early responses.
Cabozantinib Combo Shows Boost in Efficacy in Advanced Kidney Cancer SubgroupsFebruary 18th 2023
When combined with nivolumab and ipilimumab, cabozantinib appears to improve outcomes over placebo for patients with advanced, intermediate-risk renal cell cancer, and showed some efficacy among the poor-risk population.
Atezolizumab/Chemo Demonstrates Survival Trend in Urothelial CarcinomaFebruary 18th 2023
Results from the phase 3 IMvigor130 trial reveal a trend towards overall survival improvement when atezolizumab plus chemotherapy was given to patients with locally advanced or metastatic urothelial carcinoma vs placebo.
Sacituzumab Govitecan Yields Consistent Benefit in Platinum-Ineligible mUCFebruary 18th 2023
Data from the phase 2 TROPHY-U-01 trial support further evaluation of sacituzumab govitecan in patients with metastatic urothelial cancer following immune checkpoint inhibitor therapy, according to the lead investigator.
Select Biomarkers May be Predictive of Enfortumab Vedotin Efficacy in Urothelial CancerFebruary 18th 2023
Findings from the phase 2 UNITE study indicate that certain biomarkers may help inform clinical decision making and sequencing in patients with advanced urothelial carcinoma.
Niraparib Combination Continues to Improve Outcomes in Metastatic CRPCFebruary 17th 2023
Niraparib plus abiraterone and prednisone continue to improve outcomes among patients with metastatic, castration-resistant prostate cancer and HRR gene alterations, according to interim data from the MAGNITUDE study.
Darolutamide Demonstrates Long-Term Safety in Nonmetastatic CRPCFebruary 17th 2023
Long-term safety data from the phase 3 ARAMIS rollover trial support the use of darolutamide in patients with nonmetastatic castration-resistant prostate cancer, according to an expert from the Carolina Urologic Research Center.
Abiraterone Combo Shows Sustained OS Benefit in Prostate Cancer SubtypeFebruary 17th 2023
In a final overall survival analysis of the phase 3 PROpel study, abiraterone actetate/olaparib demonstrates a sustained trend toward overall survival for metastatic castration-resistant prostate cancer vs standard-of-care abiraterone.
Darolutamide/ADT Yields OS Benefit in mHSPC Across All Disease VolumesFebruary 17th 2023
Findings from the phase 3 ARASENS trial indicate that darolutamide plus androgen-deprivation therapy and docetaxel should be considered a new standard of care for metastatic hormone-sensitive prostate cancer.